|
KMID : 0923620150150060291
|
|
Immune Network
2015 Volume.15 No. 6 p.291 ~ p.303
|
|
|
The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production
|
|
:Choi Ji-Yea
:Kim Hye-Min/:Kim Ye-Jin/:Jang Mi-Rim/:Jeon Jane/:Hwang Young-Il/:Kang Jae-Seung/:Lee Wang-Jae/:Shon Won-Jun/:Song Yeong-Wook
|
|
|
Abstract
|
|
|
|
GV1001 is a peptide derived from the human telomerase reverse transcriptase (hTERT) sequence that is reported to have anti-cancer and anti-inflammatory effects. Enolase1 (ENO1) is a glycolytic enzyme, and stimulation of this enzyme induces high levels of pro-inflammatory cytokines from concanavalin A (Con A)-activated peripheral blood mononuclear cells (PBMCs) and ENO1-expressing monocytes in healthy subjects, as well as from macrophages in rheumatoid arthritis (RA) patients. Therefore, this study investigated whether GV1001 downregulates ENO1-induced pro-inflammatory cytokines as an anti-inflammatory peptide. The results showed that GV1001 does not affect the expression of ENO1 in either Con A-activated PBMCs or RA PBMCs. However, ENO1 stimulation increased the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, and these cytokines were downregulated by pretreatment with GV1001. Moreover, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB were activated when ENO1, on the surface of Con A-activated PBMCs and RA PBMCs, was stimulated, and they were successfully suppressed by pre-treatment with GV1001. These results suggest that GV1001 may be an effective anti-inflammatory peptide that downregulates the production of pro-inflammatory cytokines through the suppression of p38 MAPK and NF-κB activation following ENO1 stimulation.
|
|
|
KEYWORD
|
|
|
GV1001, ENO1, Inflammation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|